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Abstract 
Background: Clinical outcomes of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer accord-
ing to ALK fusion variants are not clear. We aimed to investigate the prevalence of ALK fusion variants and to compare 
clinical outcomes according to ALK fusion variants.
Methods: A retrospective analysis was conducted on patients with advanced ALK-rearranged adenocarcinoma 
treated with chemotherapy and ALK inhibitors. ALK rearrangement was identified by fluorescence in situ hybridiza-
tion and confirmed by immunohistochemistry. Peptide nucleic acid-mediated quantitative polymerase chain reaction 
assays, designed to detect 28 types of echinoderm microtubule-associated protein-like 4 (EML)-ALK rearrangements, 
were performed. Clinicopathological analysis and treatment outcomes with platinum-based chemotherapy, pem-
etrexed therapy, and ALK inhibitors—including crizotinib and ceritinib—were evaluated.
Results: A total of 52 patients with ALK-rearranged lung adenocarcinoma were enrolled. EML4-ALK variant 1 (v1) was 
the most common variant (38.5 %) followed by the non-EML4 variant (36.5 %), EML4-ALK variant 3a/b (19.2 %), and 
EML4-ALK variant 2 (5.8 %). No clinicopathological distinction was found between the different ALK fusion variants. 
Treatment response rates for each therapeutic agent did not differ according to ALK fusion variant. However, EML4 
variants, especially v1, showed significantly longer progression-free survival (PFS) on pemetrexed treatment than did 
non-EML4 variants (median 31.1 months versus 5.7 months, P = 0.003). PFS with platinum-based chemotherapy and 
ALK inhibitors did not differ according to ALK fusion variant. Multivariate survival analysis using Cox’s regression model 
revealed v1 as the only predictive factor for prolonged PFS on pemetrexed.
Conclusions: Among ALK fusion variants, v1 is the most common subtype. It showed superior progression-free sur-
vival on pemetrexed than did non-EML4 variants. No survival difference was demonstrated between variants treated 
with crizotinib or ceritinib.
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Background
Anaplastic lymphoma kinase (ALK) rearrangements, 
found in approximately 5  % of non-small cell lung can-
cers (NSCLCs), are relatively rare genetic alterations 
compared with epidermal growth factor receptor (EGFR) 
or KRAS mutations [1]. Soda et al. identified the echino-
derm microtubule-associated protein-like 4 (EML4)-ALK 
fusion gene, and reported its transforming activity and 
potential as a therapeutic target in NSCLCs [2]. Sub-
sequently, following reports of dramatic therapeutic 
effects of crizotinib on ALK-rearranged NSCLCs [3, 4], 
a number of studies on the clinicopathologic character-
istics of ALK-rearranged NSCLC have been conducted 
[5–8]. Currently, the fluorescence in  situ hybridiza-
tion (FISH) method is considered the gold standard for 
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establishment of ALK-rearrangement positivity. In addi-
tion, immunohistochemistry (IHC) for ALK protein is 
known to have high sensitivity and specificity for recog-
nition of ALK rearrangements and is strongly correlated 
with FISH results [9, 10]. However, FISH and IHC can-
not specify the different variants or fusion gene part-
ners of the ALK gene, which can be identified by real 
time-polymerase chain reaction (RT-PCR) or next-gen-
eration sequencing technology. Crizotinib is effective for 
NSCLC patients harboring ALK rearrangements (~60 % 
of patients achieve an objective response) but almost all 
experience disease progression after 8–11 months [3, 11, 
12]. We hypothesized that different ALK fusion variants 
would lead to different treatment responses. In the pre-
sent study, we investigated the prevalence of ALK fusion 
partners in NSCLCs, and explored whether the efficacy 
of therapeutic agents differs according to ALK fusion 
variant.
Methods
A retrospective analysis was conducted on patients with 
advanced ALK-rearranged adenocarcinoma treated with 
chemotherapy and ALK inhibitors. This retrospective 
study was approved by the Institutional Review Board of 
Severance Hospital (No. 4-2015-0926).
Clinicopathologic analysis
The following clinicopathologic parameters were 
recorded: age, sex, smoking status [never smokers, for-
mer smokers (quit smoking >1  year before diagno-
sis), and current smokers], pack-year smoking history 
(defined as the number of cigarette packs smoked per 
day multiplied by the number of years of smoking), sites 
of metastasis, and pathological tumor stage at diagno-
sis. For histological analysis, intra- and/or extracellular 
mucin, ALK-related growth patterns including cribriform 
and solid signet ring cells, features of nuclei, and psam-
momatous calcification were examined. All samples were 
reviewed by experienced pulmonary pathologists (Y.J.C. 
and H.S.S.). Treatment methods, treatment responses, 
overall survival, and progression-free survival (PFS) were 
assessed. Tumor response was determined according to 
Response Evaluation Criteria in Solid Tumors, version 
1.1 [13].
EGFR and KRAS mutation analysis
To determine the EGFR and KRAS mutation status, DNA 
was extracted from formalin-fixed, paraffin-embedded 
(FFPE) tissues using the DNeasy Isolation Kit (Qiagen, 
Valencia, CA, USA), according to the manufacturer’s 
instructions. For the EGFR gene, direct DNA sequencing 
of exons 18–21 was performed using the PNA Clamp™ 
EGFR Mutation Detection Kit (PANAGENE, Daejeon, 
Korea). For the KRAS gene, direct DNA sequencing of 
codons 12 and 13 was performed. Each tumor was classi-
fied as positive or negative for a mutation after compari-
son with the wild-type gene sequence.
ALK fluorescence in situ hybridization 
and immunohistochemistry
To identify ALK rearrangements, FISH was performed 
using a break-apart ALK probe (Vysis LSI Dual Color, 
Break Apart Rearrangement Probe; Abbott Molecular, 
Abbot Park, IL, USA). ALK rearrangement was scored as 
positive when >15 % of tumor cells displayed split or iso-
lated signals containing a kinase domain. IHC was per-
formed using an ALK antibody (rabbit monoclonal, clone 
D5F3, Cell Signaling Technology, Danvers, MA, USA) 
and Ventana automated immunostainer BenchMark XT 
(Ventana Medical Systems, Tucson, AZ, USA), as previ-
ously described [14].
RNA extraction and cDNA synthesis
Total RNA was extracted using the PureLink™ FFPE 
Total RNA Isolation Kit (Invitrogen Carlsbad, CA, USA) 
with the following protocol modifications. The resulting 
RNA was eluted in 50 µL of elution buffer. The concen-
tration and purity of the extracted RNA were determined 
by spectrophotometry. The extracted RNA was stored at 
−80  °C until required. We used 250 ng of total RNA to 
generate cDNA using the Super Script VILO cDNA syn-
thesis kit (Invitrogen).
PNA‑mediated qPCR assay for EML4‑ALK screening 
and genotyping
EML4-ALK fusion RNA was detected using the 
PANA qPCR™ EML4-ALK fusion gene detection 
Screening and Genotyping kit (PANAGENE, Dae-
jeon, Korea), designed to detect 28 known ALK rear-
rangements. Screening for and genotyping of 12 
EML4-ALK fusions was performed, including: E6;A19, 
E6;A20, E6ins33;A20(3ea), E6;ins18A20, E13;A20(5ea), 
E13;ins69A20(2ea), E20;A20(2ea), E20;ins18A20(2ea), 
E14ins11;del49A20(2ea), E14;del14A20, E14;del38A20, 
E2;A20, E2;ins117A20, E17;ins30A20, E17ins61;ins34A20, 
E17ins65;A20, E17;ins68A20, and E17del58;ins39A20. 
Reverse transcription and RT-PCR were performed in 
a CFX96 RT-PCR detection system (BIO-RAD, Foster 
city, CA, USA) under the following conditions: 2 min at 
50 °C, 15 min at 95 °C and 5 cycles of 10 s at 95 °C, 30 s at 
58 °C and 45 cycles of 10 s at 95 °C, and 30 s at 58 °C and 
15 s at 72 °C. A positive result was defined as a threshold 
cycle (Ct) value <40, and a positive internal control was 
defined as a Ct value <36. A result was regarded as invalid 
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if the assays for EML4-ALK fusion gene and internal con-
trol showed simultaneous negative results. When invalid 
results were obtained, the assay was repeated using the 
newly synthesized cDNA. The assay result was inter-
preted as positive for EML4-ALK according to the manu-
facturer’s instructions.
Statistical analysis
Clinicopathologic parameters were compared using the 
Chi square (for categorical parameters) and Mann–Whit-
ney U (for continuous parameters) tests. Survival was 
evaluated using the Kaplan–Meier method, and statisti-
cal differences in survival times were determined using 
the log-rank test. A Cox proportional hazards model 
was used to assess risk factors for PFS of each therapeu-
tic agent. Statistical analyses were performed using SPSS 
19.0 (SPSS Inc. Chicago, IL, USA), and a P value <0.05 
was considered significant.
Results
Patient selection
Between March 2000 and February 2015, ALK-rear-
rangement was confirmed in 76 patients at our insti-
tution; all had adenocarcinomas. Results of RT-PCR 
analysis for ALK fusion partners were available for 52 
of the 76 patients. These 52 patients were included: 19 
were diagnosed by transbronchial lung biopsy or fiber 
optic bronchoscopy biopsy of the primary lung tumor, 6 
by endobronchial ultrasound lymph node biopsy, 16 by 
lobectomy or wedge resection of the primary lung tumor, 
5 by pleural biopsy, and 5 by biopsy of distant metastatic 
lesions.
Clinicopathologic characteristics and ALK fusion variants
Patients’ clinicopathologic characteristics are summa-
rized in Table 1. The median age was 52 (range, 31–76) 
years and 23 (44.2 %) patients were male. Mean follow-up 
period was 43.4 ± 7.1 months (range, 2.4–347.0). Thirty-
five (67.3 %) were never smokers, 6 (11.5 %) were former 
smokers, and 11 (21.2 %) were current smokers. In terms 
of pathologic stage, 5.8 and 94.2 % of cases were stage IIIB 
and stage IV, respectively, at study start. Twenty-eight 
(53.8  %) patients had lung or pleural metastasis (M1a), 
and 35 (67.3 %) had distant metastasis (M1b) (Additional 
file 1: Table S1). The most common site of distant metas-
tasis was the brain (N  =  23, 44.2  %). The EML4-ALK 
variant 1 (v1) was the most common (N =  20, 38.5  %), 
followed by the non-EML4 variant (N  =  19, 36.5  %), 
EML4-ALK variant 3a/b (v3a/b) (N  =  10, 19.2  %), and 
EML4-ALK variant 2 (v2) (N = 3, 5.8 %) (Fig. 1).
Among the ALK fusion variants, tumors with EML4-
ALK variants showed more frequent lung and/or pleural 
involvement without distant metastasis compared with 
the non-EML4 variants (P = 0.015). Among the 22 EML4 
variant tumors with lung and/or pleural involvement, the 
majority were v1 (N = 13, 65.0 % of v1) and v3a/b (N = 8, 
80.0 % of v3a/b). Other clinicopathologic parameters and 
histologic features did not differ according to ALK fusion 
variant.
Most patients received platinum-based chemotherapy 
or pemetrexed therapy as first-line chemotherapy, before 
receiving crizotinib or ceritinib. Single-agent pemetrexed, 
EGFR tyrosine kinase inhibitors (TKIs), and single-agent 
platinum therapy were used as second-line or further lines 
of therapy. Patient treatment history before ALK inhibitor 
use is summarized in Additional file 1: Table S2.
Efficacy of chemotherapy regimens and treatment 
response, according to ALK fusion partners
Forty patients (76.9 %) received first-line platinum-based 
chemotherapy, with partial response (PR) in 10 (25.0 %), 
stable disease (SD) in 20 (50.0  %), and progressive dis-
ease (PD) in 10 (25.0  %). With regard to pemetrexed, 
35 patients (67.3  %) received pemetrexed in any line of 
treatment: 7 (20.0 %), 25 (71.4 %), and 3 (8.6 %) patients 
showed PR, SD, and PD, respectively. There were no sig-
nificant differences in objective response rate (ORR) or 
disease control rate (DCR) with platinum-based chemo-
therapy or pemetrexed, according to ALK fusion variant.
Overall, 37 patients received ALK inhibitors, including 
crizotinib (N = 32, 61.5 %), ceritinib (N = 14, 26.9 %), and 
alectinib (N  =  2, 3.8  %). ALK inhibitors were adminis-
tered as second- or further-line therapy in most patients, 
except for 8 patients who received crizotinib (N = 7) and 
ceritinib (N = 1) as first-line therapy. Five patients (two 
v1 and three v3a/b), who received crizotinib showed PD 
while most patients showed at least SD and PR to ALK 
TKI treatment. Overall, the ORR was 53.1 % with crizo-
tinib and 57.1 % with ceritinib. Treatment response rates 
to ALK inhibitors did not differ according to ALK fusion 
variant (Table 2).
A 42  year-old woman, who harbored a v2 variant, 
showed complete response (CR) to ceritinib. Her brief 
clinical history and detailed histologic features are sum-
marized in Additional file 1: Fig. S1.
Progression‑free survival with each therapeutic agent, 
according to ALK fusion variant
In patients who received first-line platinum-based chem-
otherapy, there was no significant difference in PFS 
according to ALK fusion variant (Fig.  2). With regard 
to pemetrexed, EML4-ALK fusion variants showed sig-
nificantly superior PFS compared to non-EML4 variants 
(Fig.  3a). When further analyzing the subtypes of EML4-
ALK variants, v1 showed significantly better PFS than did 
the others (Fig. 3b). No significant difference according to 
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ALK fusion variant was found in PFS of patients treated 
with crizotinib or ceritinib (Fig.  4). In the univariate Cox 
proportional hazards analyses for PFS on pemetrexed, v1 
was determined to be a predictive factor for prolonged PFS, 
while non-EML4 was identified as a risk factor for shorter 
PFS. However, in the multivariate analysis, v1 was the only 
significant predictive factor of longer PFS (Table 3).
Discussion
In the present study, patients harboring the EML4-
ALK variant, especially v1, had significantly prolonged 
PFS on pemetrexed therapy, whereas no difference in 
PFS was observed for those treated with ALK inhibi-
tors, according to the ALK fusion variants. Since FISH 
was used as the gold standard method for enrollment 
in clinical trials of ALK inhibitors, information on ALK 
fusion variants was limited in previous studies, and the 
efficacy of chemotherapy or targeted therapy accord-
ing to fusion variant was not established. In the present 
study, we confirmed the ALK rearrangements in patient 
with NSCLCs using FISH and IHC and additionally 
specified the EML4-ALK variants using RT-PCR, which 
identifies the largest number of EML4-ALK variants to 
date.
Table 1 Clinicopathologic characteristics and histological analysis
* EML4-ALK variant 1 (N = 13, 65.0 %); EML4-ALK variant 2 (N = 1, 33.3 %); EML4-ALK variant 3a/b (N = 8, 80.0 %)
Total (N = 52) EML4 variants (N = 33) Non‑EML4 variants (N = 19) P value
Clinicopathologic parameters
 Age, median (range) 52 (31–76) 50 (31–76) 55 (32–70) 0.227
 Women (%) 29 (55.8) 21 (63.6) 8 (42.1) 0.132
 Smoking history (%) and pack-years 0.904
  Never smoker 35 (67.3) 23 (69.7) 12 (63.2)
  Ex-smoker, pack-years 6 (11.5), 17.7 4 (12.1), 19.4 2 (10.5), 14.3
  Current smoker, pack-years 11 (21.2), 23.1 6 (18.2), 19.6 5 (26.3), 27.4
 Pathologic stage 0.546
  IIIB 3 (5.8) 1 (3.0) 2 (10.5)
  IV 49 (94.2) 32 (97.0) 17 (89.5)
 Metastasis sites
  Brain 23 (44.2) 14 (42.4) 9 (47.4) 0.730
  M1a sites 28 (53.8) 22 (66.7)* 6 (31.6) 0.015
  M1b sites 35 (67.3) 22 (66.7) 13 (68.4) 1.000
  M1ab sites 49 (94.2) 32 (97.0) 17 (89.5) 0.546
  Death 19 (36.5) 11 (33.3) 8 (42.1) 0.527
Histologic parameters
 Presence of mucin 10 (22.7) 5 (17.2) 5 (33.3) 0.271
  Intracellular, columnar cells 4 (9.1) 1 (3.4) 3 (20.0) 0.107
  Intracellular, signet ring cells 7 (15.9) 4 (13.8) 3 (20.0) 0.675
  Extracellular 4 (9.1) 1 (3.4) 3 (20.0) 0.107
Predominant pattern 0.443
  Acinar 15 (38.5) 8 (33.3) 7 (46.7)
  Solid 18 (46.2) 11 (45.8) 7 (46.7)
  Cribriform 4 (10.3) 4 (16.7) 0 (0.0)
  Micropapillary 2 (5.1) 1 (4.2) 1 (6.7)
 Cribriform pattern 10 (22.7) 7 (24.1) 3 (20.0) 1.000
 Solid signet rings 25 (56.8) 17 (58.6) 8 (53.3) 1.000
 Prominent nucleoli 17 (38.7) 14 (48.2) 3 (20.0) 0.136
 Psammomatous calcification 6 (13.6) 4 (13.8) 2 (13.3) 1.000
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In the present study, EML4-ALK fusion v1 was the 
most common variant, identified in 38.5 % of all patients 
and accounting for 60.6 % of all EML4-ALK variants. This 
finding is consistent with previous studies [15, 16]. Non-
EML4 variants were the second most common, identified 
in 36.5  % of patients, which is slightly higher than that 
previously reported [3, 16]. Although the RT-PCR meth-
ods used in the present study were designed to detect 28 
types of EML4-ALK rearrangements, only v1, v2, and 
v3a/b were identified in our patients. Among the EML4-
ALK variants, v3a/b and v2 were the second and third 
most common types, as previously described [3, 15].
Most of the patients in the present study received ALK 
inhibitors as second- or further-line treatment, and the 
ORR to ALK inhibitors was far better than to platinum-
based or pemetrexed chemotherapy. Crizotinib was used 
most commonly, followed by ceritinib and alectinib. Cri-
zotinib was initially developed as a c-Met inhibitor, but 
was found to be an efficient inhibitor of ALK phospho-
rylation and signal transduction [17], and to be effective 
in the treatment of ROS1-rearranged NSCLCs [18, 19]. 
Ceritinib [20, 21] and alectinib [22, 23] are second-gen-
eration ALK inhibitors that can be used in patients with 
crizotinib resistance or intolerance. In the present study, 
the treatment response rate to ALK inhibitors was no dif-
ferent between the EML4 group and non-EML4 group, 
consistent with a previous study [3]. There was also no 
difference among EML4-ALK variants. Recently, during 
preparation of our manuscript, Yoshida et al. reported on 
the frequency of ALK fusion variants and the therapeutic 
efficacy of crizotinib according to the different variants 
in patients with ALK-rearranged NSCLCs; this approach 
was similar to that of our study [16]. They evaluated 35 
patients with ALK-rearranged NSCLCs, and found that 
v1, the most common variant, was associated with supe-
rior PFS on crizotinib than non-v1 variants. This was 
not observed in our study. Further studies are required 
to investigate these discrepant findings. These two stud-
ies had similar limitations that could affect study results: 
both were retrospective studies with a small sample size. 
In addition, the treatment line for crizotinib differed 
across studies.
Although Yoshida et al. did not evaluate the therapeu-
tic efficacy of second-generation ALK inhibitors such as 
ceritinib, we examined the therapeutic efficacy of ceri-
tinib according to ALK fusion variants, and found no 
difference in the use of ceritinib as crizotinib. Notably, 
however, one patient with v2 variant achieved a CR on 
ceritinib treatment. The tumor of this patient exhibited 
an extensive papillary and micropapillary pattern with 
partly retained alveolar wall architecture, distinguishing 
it histologically from the usual pattern of ALK-rearranged 
tumors. In the present study, all v2 patients showed PR to 
crizotinib and CR to ceritinib. Moreover, both the ORR 
and DCR were 100  %, although v2 was found in only 3 
patients—too small a number to draw a general conclu-
sion. A previous in vitro study reported v2 as being the 
most sensitive to ALK inhibition, and explained that v2 
has a shorter half-life compared with the other variants 
and is far more unstable since it has the longest N-termi-
nus of EML4 [24].
Pemetrexed, a folate antimetabolite that inhibits 
enzymes used in purine and pyrimidine synthesis, has 
been approved for malignant mesothelioma and NSCLC 
of non-squamous histology. Previous studies demon-
strated an association between ALK rearrangement in 
NSCLC and prolonged PFS in patients treated with pem-
etrexed [25, 26]. The studies measured mRNA level of 
thymidylate synthase (TS), one of the catalytic enzymes 
thought to reduce sensitivity to pemetrexed, and showed 
a significantly lower TS mRNA level in ALK-rearranged 
tumor cells [26]. However, a more recent study with a 
larger cohort refuted these observations: it showed simi-
lar PFS of patients with ALK-rearranged and ALK-wild 
type NSCLCs [27]. They also measured mRNA level of 
TS and concluded that ALK rearrangement was asso-
ciated with a lower TS mRNA level, but that PFS on 
pemetrexed treatment was not affected by ALK status 
Fig. 1 Prevalence of ALK fusion variants
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[27]. So far, all previous studies on pemetrexed efficacy 
confirmed ALK rearrangement using the FISH method. 
Thus, frequency of ALK fusion variants in each study 
was unknown [25–27]. One possible scenario for the 
observed discrepancy regarding pemetrexed efficacy is 
that proportion of v1 might have differed in each pre-
vious study, because in the present study pemetrexed 
showed a significantly better PFS when used to treat v1 
variants than when used to treat other variants. Although 
we could not examine the TS level in tumors because the 
Table 2 Efficacy of ALK inhibitors according to ALK fusion variants
CTx chemotherapy; PR partial response; SD stable disease; PD progressive disease; CR complete response; ORR objective response rate; DCR disease control rate; NA 
not applicable
Total (N = 52) EML4‑ALK variant 1 
(N = 20)
EML4‑ALK variant 2 
(N = 3)
EML4‑ALK variant 
3a/b (N = 10)
Non‑EML4 variants 
(N = 19)
P value
First-line, platinum-
based CTx, N (%)
40 (76.9) 17 (85.0) 1 (33.3) 9 (90.0) 13 (68.4) 0.979
 PR 10 (25.0) 4 (23.5) 0 (0.0) 3 (33.3) 3 (23.1)
 SD 20 (50.0) 9 (52.9) 1 (100.0) 4 (44.4) 6 (46.2)
 PD 10 (25.0) 4 (23.5) 0 (0.0) 2 (22.2) 4 (30.8)
 ORR, % 25.0 23.5 0.0 33.3 23.1 0.853
 DCR, % 75.0 76.5 100.0 77.8 69.2 0.791
Received pemetrexed, 
any line, N (%)
35 (67.3) 17 (85.0) 1 (33.3) 6 (60.0) 11 (57.9) 0.591
 PR 7 (20.0) 2 (11.8) 0 (0.0) 3 (50.0) 2 (18.2)
 SD 25 (71.4) 13 (76.5) 1 (100.0) 3 (50.0) 8 (72.7)
 PD 3 (8.6) 2 (11.8) 0 (0.0) 0 (0.0) 1 (9.1)
 ORR, % 20.0 11.8 0.0 50.0 18.2 0.291
 DCR, % 91.4 88.2 100.0 100.0 90.9 1.000
Received Crizotinib, 
N (%)
32 (61.5) 10 (50.0) 2 (66.7) 8 (80.0) 12 (63.2) 0.134
 PR 17 (53.1) 3 (30.0) 2 (100.0) 4 (50.0) 8 (66.7)
 SD 10 (31.3) 5 (50.0) 0 (0.0) 1 (12.5) 4 (33.3)
 PD 5 (15.6) 2 (20.0) 0 (0.0) 3 (37.5) 0 (0.0)
 ORR, % 53.1 30.0 100.0 50.0 66.7 0.191
 DCR, % 84.4 80.0 100.0 62.5 100.0 0.109
Received Ceritinib, 
N (%)
14 (26.9) 5 (25.0) 1 (33.3) 3 (30.0) 5 (26.3) 0.723
 CR 1 (7.1) 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
 PR 7 (50.0) 2 (40.0) 0 (0.0) 2 (66.7) 3 (60.0)
 SD 4 (28.6) 2 (40.0) 0 (0.0) 1 (33.3) 1 (20.0)
 PD 1 (7.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0)
 ORR, % 57.1 50.0 100.0 66.7 62.5 NA
 DCR, % 85.7 100.0 100.0 100.0 80.0 NA
Received Alectinib, 
N (%)
2 (3.8) 0 (0.0) 0 (0.0) 1 (10.0) 1 (5.3) NA
 PR 2 (100.0) 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
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remaining tumor tissue was not available due to previous 
extensive molecular examination, further validation is 
needed to clarify the mechanism of prolonged PFS of v1 
on pemetrexed observed in the present study. Although 
crizotinib is the most efficient and verified target agent 
for patients with ALK-rearranged NSCLC, pemetrexed 
would be a good treatment option if patients harbor the 
v1 variant and cannot afford crizotinib. Subtyping ALK 
variants might predict the efficacy of pemetrexed.
Conclusions
In conclusion, our study showed different PFS on peme-
trexed treatment according to ALK fusion variant in lung 
adenocarcinoma. EML4-ALK variants, especially v1, had 
Fig. 2 Kaplan–Meier curves of progression free survival of patients treated with platinum-based chemotherapy, according to the ALK fusion vari-
ants. a EML4 (N = 27) versus non-EML4 (N = 13). b Demonstration of progression free survival of each variant (v1, N = 17; v2, N = 1; v3a/b, N = 9; 
non-EML4, N = 13). Each symbol on the plot marks a censored patient. v1, EML4-ALK variant 1; v2, EML4-ALK variant 2; v3a/b, EML4-ALK variant 3a/b
Fig. 3 Kaplan–Meier curves of progression free survival of patients treated with pemetrexed as any line, according to the ALK fusion variants. a 
EML4 (N = 24) versus non-EML4 (N = 11). b Demonstration of progression free survival of each variant (v1, N = 17; v2, N = 1; v3a/b, N = 6; non-
EML4, N = 11). Each symbol on the plot marks a censored patient. v1, EML4-ALK variant 1; v2, EML4-ALK variant 2; v3a/b, EML4-ALK variant 3a/b
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superior PFS than the other variants. We found no differ-
ence in PFS with ALK inhibitors according to ALK fusion 
variant. Further studies with large cohorts are required 
to confirm the different efficacy of pemetrexed or ALK 
inhibitors according to ALK fusion variants.
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